DERMATOLOGY CLINICAL RESEARCH EXCELLENCE
Revolutionize Early Phase Topical Dermatology Trials
Efficacy insights in days, not months.
Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≤3 days, and lowers costs, helping teams make informed go/no-go decisions faster.
Schedule a complimentary 30-minute consultation.
Why Choose Indero's Early Phase 1 Model for Topical Drug Development?
Indero’s Early Phase 1 model compresses timelines and enhances decision confidence. By integrating microdosing on localized skin areas with tape‑strips sampling and RNA‑seq, we detect early pharmacodynamic activity, well in advance of traditional clinical endpoints
Key benefits:
- Speed: Detect a molecular efficacy signal in ≤72 hours
- Cost‑efficiency: 3‑day studies, fewer patients, single site
- Regulatory advantage: Early human data via exploratory/early phase 1; limited nonclinical requirements relative to traditional approaches
- Flexibility: Intra‑patient design to compare multiple NCEs, concentrations, and vehicles on different sites in the same patient
- Decision clarity: Transcriptomic endpoints objectively guide go/no-go decisions, program prioritization, and study design.
CASE STUDY
Proof in Practice: Rapid Signal in Dermatology
In this internally-founded study, Indero’s team demonstrated that transcriptomic changes consistent with improved immune dysregulation could be detected within ≤72 hours after microdosed topical application in atopic dermatitis, supporting the model’s sensitivity and speed.
NCT05844618
Presented as oral & poster at ISDS; collaboration with leading academic expert
Dr. Emma Guttman
(Mount Sinai)
≤72h molecular signal using tape‑strips & RNA‑seq
Intra‑patient design enabled controlled comparisons on different skin sites
